Trial · NCT04925375
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | High Resolution CT Scan of the chest (HRCT) | 6 months | Proportion of subjects achieving a significant response (defined as \>30 percent change in lung tissue disease burden by GLILD) on HRCT after 6 months of abatacept therapy. |
| Secondary | Forced vital capacity (FVC) | 6 months, 12 months | Forced vital capacity (FVC) |
| Secondary | Forced expiratory volume (FEV) | 6 months, 12 months | Forced expiratory volume (FEV) |
| Secondary | Diffusion capacity of carbon monoxide (DLCo) | 6 months, 12 months | Diffusion capacity of carbon monoxide (DLCo) |
| Secondary | Incidence | 6 months, 12 months | Incidence of new onset autoimmune/inflammatory diseases while on abatacept or placebo |
| Secondary | Resolution | 6 months, 12 months | Resolution of existing autoimmune/inflammatory diseases while on abatacept or placebo |
| Secondary | Change in Short Form-36 scores | 6 months, 12 months | Short Form-36: scoring ranges from 0-100 where a higher score denotes better health |
| Secondary | Change in PedsQL (Pediatric Quality of Life) Generic Core scores | 6 months, 12 months | PedsQL Generic Core Scales: items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL. Range of 0-2300 for ages above 4, range of 0-2100 for 4 years old |
| Secondary | Change in King's Interstitial Lung Disease scores | 6 months, 12 months | King's Interstitial Lung Disease: scoring ranges from 0-100 where a higher score denotes better health |
| Secondary | Steroid usage | 6months, 12 months | Cumulative number of steroids used after 6 months and 12 months |
| Secondary | Survival | 6 months, 12 months | Survival at 12 months |
| Secondary | Pediatric growth - change in height | 6 months, 12 months | Change in height at 6 and 12 months. |
| Secondary | Pediatric growth - change in weight | 6 months, 12 months | Change in weight at 6 and 12 months. |
| Secondary | Additional Immune Agents | 6 months, 12 months | Rate of discontinuation of additional immune agents while on study agent |
| Secondary | Adverse Events/Serious Adverse Events | 6 months, 12 months | Incidence of adverse events and severe adverse events, compared to placebo |
| Secondary | Dropout rate | 6 months, 12 months | Study dropout rate |
| Secondary | Incidence of concurrent infections | 6 months, 12 months | Incidence of concurrent infections while on study |
| Secondary | Treatment of concurrent infections | 6 months, 12 months | Number of infections per patient which require treatment with antibiotics |
| Secondary | Complications of concurrent infections | 6 months, 12 months | Complications of concurrent infections while on study |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04925375/registered